• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzylamines

Recent Advances in the Study of 4-(2-chlorophenyl)-N-(4-fluorophenyl)methyl-1,3-thiazol-2-amine (CAS: 852388-96-6)

The compound 4-(2-chlorophenyl)-N-(4-fluorophenyl)methyl-1,3-thiazol-2-amine (CAS: 852388-96-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This thiazole derivative, characterized by its unique structural features, has shown promising potential in various therapeutic applications. Recent studies have focused on elucidating its mechanism of action, pharmacokinetic properties, and therapeutic efficacy, making it a compound of considerable interest for drug development.

One of the key areas of research has been the compound's interaction with specific biological targets. Preliminary findings suggest that 4-(2-chlorophenyl)-N-(4-fluorophenyl)methyl-1,3-thiazol-2-amine exhibits selective binding affinity towards certain kinase enzymes, which are implicated in a range of pathological conditions, including cancer and inflammatory diseases. This selectivity is attributed to the compound's ability to form stable interactions with the ATP-binding sites of these kinases, thereby modulating their activity.

In vitro and in vivo studies have further demonstrated the compound's potential as a therapeutic agent. For instance, recent experiments conducted on cell lines have shown that 4-(2-chlorophenyl)-N-(4-fluorophenyl)methyl-1,3-thiazol-2-amine can inhibit the proliferation of cancer cells by inducing apoptosis and cell cycle arrest. These effects were observed at micromolar concentrations, indicating its potency. Additionally, animal studies have revealed favorable pharmacokinetic profiles, including good oral bioavailability and moderate half-life, which are critical for its development as a drug candidate.

Another noteworthy aspect of this compound is its synthetic accessibility. Researchers have developed efficient synthetic routes to produce 4-(2-chlorophenyl)-N-(4-fluorophenyl)methyl-1,3-thiazol-2-amine with high yields and purity. These methods often involve multi-step reactions, including the formation of the thiazole ring and subsequent functionalization. The scalability of these synthetic procedures is a significant advantage for large-scale production, which is essential for further preclinical and clinical studies.

Despite these promising findings, challenges remain in the development of 4-(2-chlorophenyl)-N-(4-fluorophenyl)methyl-1,3-thiazol-2-amine as a therapeutic agent. Issues such as potential off-target effects, metabolic stability, and toxicity profiles need to be thoroughly investigated. Ongoing research is focused on optimizing the compound's structure to enhance its selectivity and reduce adverse effects. Computational modeling and structure-activity relationship (SAR) studies are being employed to guide these modifications.

In conclusion, 4-(2-chlorophenyl)-N-(4-fluorophenyl)methyl-1,3-thiazol-2-amine (CAS: 852388-96-6) represents a promising candidate for further drug development. Its unique chemical structure, combined with its demonstrated biological activity, makes it a valuable subject of study in the field of chemical biology and pharmaceutical research. Future studies will likely focus on advancing this compound through the drug development pipeline, with the ultimate goal of translating these findings into clinically viable therapies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)